Predicting the no-reflow phenomenon following successful percutaneous coronary intervention

Biomarkers in Medicine

Volumn 4, Issue 3, 2010, Pages 403-420

  Galiuto, L ^a   Paraggio, L ^a   Liuzzo, G ^a   De Caterina, A R ^a   Crea, F ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Biomarkers; Microvascular damage; No reflow; Reperfusion injury

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CONTRAST MEDIUM; CREATINE KINASE MB; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; FIBRINOGEN; GADOLINIUM; GLUCOSE; THROMBOPLASTIN; THROMBOXANE A2; TRACER; TROPONIN I; TROPONIN T; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ATHEROSCLEROTIC PLAQUE; COMPLEMENT ACTIVATION; CONTRAST ECHOCARDIOGRAPHY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; ELECTROCARDIOGRAM; GLUCOSE BLOOD LEVEL; HEART MUSCLE REPERFUSION; HUMAN; HYPERCOAGULABILITY; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTE COUNT; MICROVASCULATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; BLOOD CELL COUNT; ECHOCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; NO-REFLOW PHENOMENON; PREDICTIVE VALUE OF TESTS;

EID: 77953730738     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.55     Document Type: Review

References (126)

1. Goldberg RJ, Glatfelter K, Burbank-Schmidt E, Lessard D, Gore JM: Trends in community mortality due to coronary heart disease. Am. Heart J. 151, 501-507 (2006).
2. Armstrong PW, Granger CB, Adams PX et al.: Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297, 43-51 (2007).
3. Galiuto L, DeMaria AN, Iliceto S: Microvascular damage during myocardial ischemia-reperfusion: pathophysiology, clinical implications and potential therapeutic approach evaluated by myocardial contrast echocardiography. Ital. Heart J. 1(2), 108-116 (2000).
4. Ito H, Maruyama A, Iwakura K et al.: Clinical implications of the no-reflow phenomenon. A predictor of complications and left ventricular remodelling in reperfused anterior wall myocardial infarction. Circulation 93, 223-228 (1996).
5. Kushner FG, Hand M, Smith SC Jr et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Circulation 120, 2271-2306 (2009).
6. Van de Werf F, Bax J, Betriu A et al.: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur. Heart J.29(3), 2909-2945 (2008).
7. Kloner RA, Ganote CE, Jennings RB: The no-reflow phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 54, 1496-1508 (1974).
8. Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G: Coronary microembolization. Basic Res. Cardiol. 101, 373-382 (2006).
9. Hori M, Inoue M, Kitakaze M et al.: Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am. J. Physiol. 250, H509-H518 (1986).
10. Ambrosio G, Weisman HF, Mannisi JA, Becker LC: Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 80, 1846-1861 (1989).
11. Engler RL, Schmid-Schonbein GW, Pavelec RS: Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am. J. Pathol. 111, 98-111 (1983).
12. Ambrosio G, Tritto I: Reperfusion injury: experimental evidence and clinical implications. Am. Heart J. 138, S69-S75 (1999).
13. Nakamura TY, Goda K, Okamoto T et al.: Contractile and morphological impairment of cultured fetal mouse myocytes induced by oxygen radicals and oxidants. Correlation with intracellular Ca2+ concentration. Circ. Res. 73(4), 758-770 (1993).
14. Collet JP, Montalescot G: The acute reperfusion management of STEMI in patients with impaired glucose tolerance and Type 2 diabetes. Diabetes Vasc. Dis. Res. 2, 136-143 (2005).
15. Golino P, Maroko PR, Carew TE: The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation 75, 292-298 (1987).
16. Colonna P, Cadeddu C, Montisci R et al.: Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. Am. Heart J. 144(5), 796-803 (2002).
17. Karila-Cohen D, Czitrom D, Brochet E et al.: Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. Eur. Heart J. 20, 1724-1730 (1999).
18. Vignali L, Talanas G, Saia F et al.: Genetic association between the 1976T-C polymorphism in the adenosine A2 receptor and angiographic no-reflow phenomenon. Il Giornale Italiano di Cardiologia Invasiva 3(Suppl. 1), 109 (2007).
19. Zalewski J, Undas A, Godlewski J, Stepien E, Zmudka K: No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler. Thromb. Vasc. Biol. 27, 2258-2265 (2007).
20. Galiuto L, Lombardo A, Maseri A et al.: Temporal evolution and functional outcome of no-reflow: sustained and spontaneously reversible patterns following successful coronary recanalization. Heart 89, 731-737 (2003).
21. Schroder R: Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110, e506-e510 (2004).
22. Giugliano RP, Sabatine MS, Gibson CM et al.: Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am. J. Cardiol. 93, 1362-1367 (2004).
23. The TIMI Study Group: The Thrombolysis In Myocardial Infarction [TIMI] trial. Phase I findings. N. Engl. J. Med. 312, 932-936 (1985).
24. vant Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F; Zwolle Myocardial Infarction Study Group: Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 9 7, 2302-2306 (1998). (Pubitemid 28280383)
25. Albert TS, Kim RJ, Judd RM: Assessment of no-reflow regions using cardiac MRI. Basic Res. Cardiol. 101, 383-390 (2006).
26. Porto I, Burzotta F, Brancati M et al.: Relation of myocardial blush grade to microvascular perfusion and myocardial infarct size after primary or rescue percutaneous coronary intervention. Am. J. Cardiol. 99, 1671-1673 (2007).
27. Iliceto S, Marangelli V, Marchese A, Amico A, Galiuto L, Rizzon P: Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications. Eur. Heart J. 17, 344-353 (1996).
28. Hayat SA, Senior R: Myocardial contrast echocardiography in ST elevation myocardial infarction: ready for prime time? Eur. Heart J. 29, 299-314 (2008).
29. Galiuto L, Fedele F, Agati L; AMICI Investigators: The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J. Am. Coll. Cardiol. 51(5), 552-559 (2008).
30. Shintani Y, Ito H, Iwakura K et al.: Usefulness of impairment of coronary microcirculation in predicting left ventricular dilation after acute myocardial infarction. Am. J. Cardiol. 93(8), 974-978 (2004).
31. Fearon WF, Shah M, Ng M et al.: Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 51(5), 560-565 (2008).
32. Ito H, Tomooka T, Sakai N et al.: Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 85, 1699-1705 (1992).
33. Bolognese L, Carrabba N, Parodi G et al.: Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 109, 1121-1126 (2004).
34. Burzotta F, Trani C, Romagnoli E et al.: Manual thrombus aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J. Am. Coll. Cardiol. 46, 371-376 (2005).
35. Galiuto L, Garramone B, Burzotta F et al.; REMEDIA Investigators: thrombus aspiration reduces microvascular obstructionafter primary coronary intervention: a myocardial contrast echocardiography substudy of the REMEDIA Trial. J. Am. Coll. Cardiol. 48(7), 1355-1360 (2006).
36. Kaltoft A, Bottcher M, Nielsen SS et al.: Routine thrombectomy in percutaneous coronary intervention for acute ST-segmentelevation myocardial infarction: a randomized, controlled trial. Circulation 114(1), 40-47 (2006).
37. Loubeyre C, Morice MC, Lefevre T, Piechaud JF, Louvard Y, Dumas P: A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. J. Am. Coll. Cardiol. 39, 15-21 (2002).
38. Thiele H, Schindler K, Friedenberger J et al.: Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118, 49-57 (2008).
39. Marzilli M, Orsini E, Marraccini P, Testa R: Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101, 2154-2159 (2000).
40. Pasceri V, Pristipino C, Pelliccia F et al.: Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am. J. Cardiol. 95, 1358-1361 (2005).
41. Ito H, Taniyama Y, Iwakura K et al.: Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J. Am. Coll. Cardiol. 33, 654-660 (1999).
42. Sezer M, Oflaz H, Goren T et al.: Intracoronary streptokinase after primary percutaneous coronary intervention. N. Engl. J. Med. 356(18), 1823-1834 (2007).
43. Piot C, Croisille P, Staat P et al.: Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med. 359(5), 473-481 (2008).
44. Cura FA, L'Allier PL, Kapadia SR et al.: Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am. J. Cardiol. 88, 124-128 (2001).
45. Brener SJ, Moliterno DJ, Aylward PE et al.: Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. Eur. Heart J. 29, 1127-1135 (2008).
46. Nallamothu BK, Bradley EH, Krumholz HM: Time to treatment in primary percutaneous coronary intervention. N. Engl. J. Med. 357, 1631-1638 (2007).
47. Tarantini G, Cacciavillani L, Corbetti F et al.: Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J. Am. Coll. Cardiol. 46(7), 1229-1235 (2005).
48. Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL: Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J. Am. Coll. Cardiol. 40, 1748-1754 (2002).
49. Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Uman VA: Impaired glucose metabolism predicts mortality after a myocardial infarction. Int. J. Cardiol. 79, 207-214 (2001).
50. Ceriello A: Acute hyperglycaemia: a 'new' risk factor during myocardial infarction. Eur. Heart J. 26, 328-331 (2005).
51. Iwakura K, Ito H, Ikushima M: Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 41, 1-7 (2003). (Pubitemid 36044395)
52. Ishihara M, Kojima S, Sakamoto T: Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am. Heart J. 81, 814-820 (2005). (Pubitemid 41396520)
53. Takahashi T, Hiasa Y, Ohara Y et al.: Acute hyperglycemia prevents the protective effect of pre-infarction angina on microvascular function after primary angioplasty for acute myocardial infarction. Heart 94, 1402-1406 (2008).
54. Undas A, Wiek I, Stepien E: Hyperglycemia is associated with enhanced thrombin formation, platelet activation and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diab. Care 31, 1590-1595 (2008).
55. Iwakura K, Ito H, Kawano S et al.: Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J. Am. Coll. Cardiol. 38, 472-477 (2001).
56. Yip HK, Chen MC, Wu CL: Angiographic morphologic features of infarct-related arteries and timely reperfusion in AMI. Chest 122, 1322-1332 (2002).
57. Maekawa Y, Asakura Y, Anzai T et al.: Relation of stent overexpansion to the angiographic no-reflow phenomenon in intravascular ultrasound-guided stent implantation for acute myocardial infarction. Heart Vessels 20(1), 13-18 (2005).
58. Bradbury J: Renewed interest in leucocyte count as prognostic indicator after AMI. Lancet 358, 1787 (2001).
59. Zalokar JB, Richard JL: Leukocyte count, smoking, and myocardial infarction. N. Eng. J. Med. 304, 465-468 (1981).
60. Yarnell JW, Baker IA, Sweetnam PM et al.: Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell collaborative heart studies. Circulation 83, 836-844 (1991).
61. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM: Association between white blood cell count, epicardial blood flow, myocardial perfusion and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 102, 2329-2334 (2000).
62. Buffon A, Biasucci LM, Liuzzo G et al.: Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 347, 5-12 (2002).
63. Mehta JL, Nichols WW, Mehta P: Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. J. Am. Coll. Cardiol. 11, 1309-1316 (1988).
64. Frangogianis NG, Youker KA, Rossen RD et al.: Cytokines and microcirculation in ischemia and reperfusion. J. Mol. Cell Cardiol. 30, 2567-2576 (1998).
65. Kojima S, Sakamoto T, Ishihara M et al.: The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era. Ann. Med. 36, 153-160 (2004).
66. Sezer M, Okcular I, Umman S: Association of haematological indices with the degree of microvascular injury in patients with acute anterior wall myocardial infarction treated with primary percutaneous coronary intervention. Heart 93, 313-318 (2007).
67. Zhang R, Brennan ML, FuX et al.: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 106, 2894-2900 (2001).
68. Funayama H, Ishikawa S, Sugawara Y et al.: Myeloperoxidase may contribute to the no-reflow phenomenon in patients with acute myocardial infarction. Int. J. Cardiol. 139(2), 187-192 (2008).
69. Van der Loo B, Martin JF: A role for changes in platelet production in the cause of acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 19, 672-679 (1999).
70. Giles H, Smith REA, Martin JF: Platelet glycoprotein IIb/IIIa and size are increased in acute myocardial infarction. Eur. J. Clin. Invest. 24, 69-72 (1994).
71. Pizzuli L, Yang A, Martin JF, Luderitz B: Changes in platelet size and count in unstable angina compared with stable or non-cardiac chest pain. Eur. Heart J. 19, 80-84 (1998).
72. Endler G, Klimesch A, Saunder-Plassman A et al.: Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br. J. Haematol. 117, 399-404 (2002).
73. Pabon P, Nieto F, Morinigo JL et al.: The effect of mean platelet volume on the short-term prognosis of acute myocardial infarction. Rev. Esp. Cardiol. 51, 816-822 (1998).
74. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N. Engl. J. Med. 357, 1121-1135 (2007).
75. Huczek Z, Kochman J, Filipiak KJ et al.: Mean platelet volume on admission predicts impaired reperfusion and long term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 46, 284-290 (2005).
76. Niccoli G, Giubilato S, Russo E et al.: Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur. Heart J. 29, 1843-1850 (2008).
77. Vilahur G, Casani L, Badimon L: A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb. Haemost. 98(3), 662-669 (2007).
78. Meier MA, Al-Badr WH, Cooper JV et al.: The new definition of myocardial infraction. Diagnostic and prognostic implications in patients with acute coronary syndromes. Arch. Intern. Med. 162, 1585-1589 (2002).
79. Trevelyan J, Needham EWA, Smith SCH et al.: Sources of diagnostic inaccuracy of conventional versus new diagnostic criteria for myocardial infarction in an unselected UK population with suspected cardiac chest pain, and investigation of independent prognostic variables. Heart 89, 1406-1410 (2003).
80. Jesel L, Morel O, Ohlmann P et al.: Role of pre-infarction angina and inflammatory status in the extent of microvascular obstruction detected by MRI in myocardial infarction patients treated by PCI. Int. J. Cardiol. 121, 139-147 (2007).
81. Olszowska M, Tracz W: Predictive factors of myocardial reperfusion in patients with anterior wall acute myocardial infarction. Cardiol. J. 15, 57-62 (2008).
82. Collinson PO, Boa FG, Gaze DC: Measurement of cardiac troponins. Ann. Clin. Biochem. 38, 423-449 (2001).
83. Ohman EM, Topol EJ, Califf RM et al.: Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N. Engl. J. Med. 335, 1333-1341 (1996).
84. Stubbs P, Collinson P, Moseley D et al.: Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 94, 1291-1297 (1996).
85. Kurowski V, Hartmann F, Killermann DP et al.: Prognostic significance of admission cardiac troponin T in patients treated successfully with direct percutaneous interventions for acute ST-segment elevation myocardial infarction. Crit. Care Med. 30(10), 2385-2387 (2002).
86. Tanasijevic MJ, Cannon CP, Antman EM et al.; TIMI 10B Investigators: Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the thrombolysis in myocardial infarction study (TIMI) 10B. J. Am. Coll. Cardiol. 34, 739-747 (1999).
87. Stewart JT, French JK, Theroux P et al.: Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. J. Am. Coll. Cardiol. 31, 1499-1505 (1998).
88. Matetzky S, Sharir T, Domingo M et al.: Elevated troponin I level on admission is associated with adverse out come of primary agioplasty in acute myocardial infarction. Circulation 102, 1611-1616 (2000).
89. Giannitsis E, Muller-Bardorff M, Lehrke S et al.: Admission troponin T level predicts clinical outcomes, TIMI flow and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 104, 630-635 (2001).
90. Hong SN, Ahn Y, Hwang SH et al.: Usefulness of preprocedural N-terminal pro-brain peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction. Am. J. Cardiol. 100, 631-634 (2007).
91. Porto I, Burzotta F, Trani C et al.: Elevated admission cardiac troponin T is associated with microvascular dysfunction in acute myocardial infarction treated with emergency angioplasty. J. Cardiovasc. Med. (Hagerstown). 10(8), 664-668 (2009).
92. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105, 1135-1143 (2002).
93. Tomai F, Ribichini F, Ghini AS et al.: Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease. Eur. Heart J. 26, 2099-2105 (2005).
94. Sturk A, Hack CE, Aarden LA, Brouwer M, Koster RR, Sanders GT: Interleukin-6 release and the acute-phase reaction in patients with acute myocardial infarction: a pilot study. J. Lab. Clin. Med. 119, 574-579 (1992).
95. Speidl WS, Zeiner A, Nikfardjam M et al.: An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J. Am. Coll. Cardiol. 45, 30-34 (2005).
96. Lagrand WK, Niessen HW, Wolbink GJ et al.: C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95, 97-103 (1997).
97. De Sutter J, De Buyezere M, Gheeraert P et al.: Fibrinogen and C-reactive protein on admission as marker of final infarct size after primary angioplasty for acute myocardial infarction. Atherosclerosis 157, 189-196 (2001).
98. Theroux P, Armstrong PW, Mahaffey KW et al.: Prognostic significance of blood markers of inflammation in patients with STsegment elevation myocardial infarction undergoing primary angioplasty and effects of pexeluzimab, a C5 inhibitor: a substudy of the COMMA trial. Eur. Heart J. 26(19), 1964-1970 (2005).
99. Qamirani E, Ren Y, Kuo L, Hein TW: C-reactive protein inhibits endotheliumdependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler. Thromb. Vasc. Biol. 25, 995-1001 (2005).
100. Celik T, Iyisoy A, Kursaklioglu H et al.: The impact of admission C-reactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Coron. Artery Dis. 16, 293-299 (2005).
101. Niccoli G, Lanza GA, Spaziani C, Crea F: Baseline sistemi inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int. J. Cardiol. 117, 306-311 (2007).
102. Wasilewski J, Turczynski B, Kowalik V et al.: Evaluation of hemorpheological profiles in patients with no-reperfusion phenomenon in acute ST elevation myocardial infarction treated by primary percutaneous coronary intervention. J. Vasc. Biol. 42(Suppl. 2), 49 (2005).
103. Soutani M, Suzuki Y, Tateishi N et al.: Quantitative evaluation of flow dynamics of erythrocytes in microvessels: influence of erythrocyte aggregation. Am. J. Physiol. 268, H1959-H1965 (1995).
104. De Sutter J, De Buyzere M, Gheeraert P et al.: Fibrinogen and C-reactive protein on admission as markers of final infarct size after primary angioplasty for acute myocardial infarction. Atherosclerosis 157, 189-196 (2001).
105. Wasilewski J, Osadnik T, Polonski L: High baseline fibrinogen concentration as a risk factor of no tissue reperfusion in ST-segment elevation acute myocardial infarction treated with successful primary percutaneous coronary intervention. Kardiol. Pol. 64, 967-972 (2006).
106. Sgueglia GA, Niccoli G, Spaziani C, Crea F et al.: Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction. Int. J. Cardiol. (2009) (Epub ahead of print).
107. Yanagisawa M, Kurihara H, Kimura S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415 (1988).
108. Resink TJ, Hahn AW: Scott-Burden T, Powell J, Weber E, Buhler FR: Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 168, 1303-1310 (1990). (Pubitemid 20176022)
109. Winkles JA, Alberts GF, Brogi E, Libby P: Endothelin 1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem. Biophys. Res. Commun. 191, 1081-1088 (1993).
110. Molenaar P, O'Reilly G, Sharkey A et al.: Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ. Res. 72, 526-538 (1993).
111. Sugden PH, Bogoyevitch MA: Endothelin-ldependent signaling pathways in the myocardium. Trends Cardiovasc. Med. 6, 87-94 (1996).
112. Hasdai D, Kornowski R, Battler A: Endothelin and myocardial ischemia. Cardiovasc. Drugs Ther. 8, 589-599 (1994).
113. Grover GJ, Dzwonczyk S, Parham CS: The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc. Res. 27, 1613-1618 (1993).
114. Krause SM, Lynch JJ, Stabilito II et al.: Intravenous administration of the endothelin-1 antagonist BQ-123 does not ameliorate myocardial ischaemic injury following acute coronary artery occlusion in the dog. Cardiovasc. Res. 28, 1672-1678 (1994).
115. Galiuto L, DeMaria AN, Iliceto S: Ischemiareperfusion injury at the microvascular level: treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation 102, 3111-3116 (2000).
116. Niccoli G, Lanza GA, Shaw S, Crea F et al.: Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur. Heart J. 27, 1793-1798 (2006).
117. Adlbrecht C, Bonderman D, Plass C et al.: Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb. Haemost. 97(4), 642-649 (2007).
118. Edgington TS, Mackman N, Brand K, Ruf W: The structural biology of expression and function of tissue factor. Thromb. Haemost. 66, 67-79 (1991).
119. Carson SD, Brozna JP: The role of tissue factor in the production of thrombin. Blood Coagul. Fibrinolysis 4, 281-292 (1993).
120. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A: Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 99, 348-353 (1999).
121. Bonderman D, Teml A, Jakowitsch J et al.: Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood. 99(8), 2794-2800 (2002).
122. James SK, Lindahl B, Siegbahn A et al.: N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation 108, 275-281 (2003).
123. Omland T, de Lemos JA, Morrow DA et al.: Prognostic value of N-terminal pro-atrial and probrain natriuretic peptide in patients with acute coronary syndromes. Am. J. Cardiol. 89, 463-465 (2002). (Pubitemid 34142525)
124. Goetze JP, Christoffersen C, Perko M et al.: Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 17, 1105-1107 (2003).
125. Grabowski M, Filipiak KJ, Karpinski G: Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am. Heart J. 148, 655-662 (2004).
126. Jeong YH, Kim WJ, Park DW: Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction. Int. J. Cardiol. (2009) (Epub ahead of print).